BioMarin price target raised to $145 from $132 at Leerink. Leerink analyst Joseph Schwartz raised his price target to $145 from $132 to reflect new price assumptions for Valrox in hemophilia A following discussions with MEDACorp payor specialists. The analyst reiterates an Outperform rating on the shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.